Pharmacological characterization of a fluorescent uptake assay for the noradrenaline transporter

Journal of Biomolecular Screening

Volumn 12, Issue 3, 2007, Pages 378-384

  Haunsø, Anders ^a   Buchanan, Dawn ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Biogenic; Monoamine; Noradrenaline; Norepinephrine; Transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 (4 DIMETHYLAMINOSTYRYL) N METHYLPYRIDINIUM; AMFONELIC ACID; AMINOREX; AMOXAPINE; AMPHETAMINE; ATOMOXETINE; CHLORAMPHETAMINE; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; COCAINE; DESIPRAMINE; DOPAMINE; IMIPRAMINE; MAPROTILINE; MAZINDOL; METHYLPHENIDATE; MILNACIPRAN; NISOXETINE; NOMIFENSINE; NORADRENALIN; NORADRENALIN TRANSPORTER; PAROXETINE; PHENTERMINE; PYRIDINIUM DERIVATIVE; REBOXETINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL CELL; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG POTENCY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; ISOTOPE LABELING; MODULATION; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PLATING MEDIUM; PRIORITY JOURNAL; PROTEIN TRANSPORT; RADIOACTIVITY; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE;

ANIMALS; BIOLOGICAL ASSAY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; HUMANS; KINETICS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PSYCHOTROPIC DRUGS; PYRIDINIUM COMPOUNDS; TRITIUM;

EID: 34047128106     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107299524     Document Type: Article

References (22)

1. Masson J., Sagne C., Hamon M., El Mestikawy S.: Neurotransmitter transporters in the central nervous system. Pharmacol Rev 1999 ; 51: 439-464.
2. Gainetdinov RR, Caron MG: Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 2003 ; 43: 261-284.
3. Nelson N.: The family of Na+/Cl- neurotransmitter transporters. J Neurochem 1998 ; 71: 1785-1803.
4. Iversen L.: Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000 ; 5: 357-362.
5. Tatsumi M., Groshan K., Blakely RD, Richelson E.: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997 ; 340: 249-258.
6. Aston-Jones G., Rajkowski J., Cohen J.: Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 1999 ; 46: 1309-1320.
7. Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999 ; 46: 1219-1233.
8. Southwick SM, Bremner JD, Rasmusson A., Morgan CA III, Arnsten A., Charney DS: Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 1999 ; 46: 1192-1204.
9. Iversen L.: Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 2006 ; 147 (Suppl 1). S82 - S88.
10. Lee CM, Javitch JA, Snyder SH: Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes. J Neurosci 1982 ; 2: 1515-1525.
11. Pacholczyk T., Blakely RD, Amara SG: Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature 1991 ; 350: 350-354.
12. Reith ME, Wang LC, Dutta AK: Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity. J Neurosci Methods 2005 ; 143: 87-94.
13. Allan L., Leith JL, Papakosta M., Morrow JA, Irving NG, McFerran BW,, et al. Development of a novel high-throughput assay for the investigation of GlyT-1b neurotransmitter transporter function. Comb Chem High Throughput Screen 2006 ; 9: 9-14.
14. Benjamin ER, Skelton J., Hanway D., Olanrewaju S., Pruthi F., IIyin IV,, et al. Validation of a fluorescent imaging plate reader membrane potential assay for high-throughput screening of glycine transporter modulators. J Biomol Screen 2005 ; 10: 365-373.
15. Hohage H., Stachon A., Feidt C., Hirsch JR, Schlatter E.: Regulation of organic cation transport in IHKE-1 and LLC-PK1 cells: fluorometric studies with 4-(4-dimethylaminostyryl)-N-methylpyridinium. J Pharmacol Exp Ther 1998 ; 286: 305-310.
16. Mason JN, Farmar H., Tomlinson ID, Schwartz JW, Savchenko V., DeFelice LJ,, et al. Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J Neurosci Methods 2005 ; 143: 3-25.
17. Schwartz JW, Blakely RD, DeFelice LJ: Binding and transport in norepinephrine transporters: real-time, spatially resolved analysis in single cells using a fluorescent substrate. J Biol Chem 2003 ; 278: 9768-9777.
18. Cheng Y., Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973 ; 22: 3099-3108.
19. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
20. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI,, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001 ; 39: 32-41.
21. Inazu M., Takeda H., Matsumiya T.: Functional expression of the norepinephrine transporter in cultured rat astrocytes. J Neurochem 2003 ; 84: 136-144.
22. Paczkowski FA, Bryan-Lluka LJ, Porzgen P., Bruss M., Bonisch H.: Comparison of the pharmacological properties of cloned rat, human, and bovine norepinephrine transporters. J Pharmacol Exp Ther 1999 ; 290: 761-767.